Chief Strategy & Financial Officer Recruited to Elicio by Occam Global

Elicio Therapeutics (Nasdaq: ELTX) is a clinical-stage biopharmaceutical company leveraging its highly innovative lymph node–targeting Amphiphile (AMP) platform to develop novel immunotherapies for the most prevalent cancers. In March 2025, Occam Global helped recruit Preetam Shah, PhD, as Chief Strategy and Financial Officer.

‍
Preetam brings to Elicio 20 years of distinguished financial and business development experience. Prior to Elicio, Preetam held the CFO and CBO roles at Cidara Therapeutics, following an earlier career in healthcare consulting and investment banking.

Preetam holds a PhD in microbiology from the University of Mississippi and an MBA from the University of Pennsylvania's Wharton School.

‍

About Elicio Therapeutics

‍

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical successes in the personalized cancer vaccine space to develop effective, off-the-shelf vaccines. Elicio’s Amphiphile (“AMP”) technology aims to enhance the education, activation, and amplification of cancer-specific T cells relative to conventional vaccination strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 lead program is an off-the-shelf vaccine candidate targeting the most common KRAS mutations, which drive approximately 25% of all solid tumors. ELI-002 is being studied in an ongoing, randomized clinical trial in patients with mKRAS-positive pancreatic cancer who completed standard therapy but remain at high risk of relapse. Elicio’s pipeline includes additional off-the-shelf therapeutic cancer vaccines, including ELI-007 and ELI-008, that target BRAF-driven cancers and p53 hotspot mutations, respectively. For more information, please visit www.elicio.com.